Skip to site menu Skip to page content

GSK reports rise in profit in Q2 2023

The company's turnover increased by 4% to £7.2bn in Q2 2023.

RanjithKumar Dharma July 27 2023

British pharmaceutical company GlaxoSmithKline (GSK) has reported an adjusted operating profit of £2.17bn in Q2 2023, an almost 8% increase from the £2.0bn reported in the same period of 2022.

In Q2 2023, the company's turnover increased by 4% to £7.2bn compared with £6.9bn in the same quarter of the previous year.

The firm disclosed an adjusted operating margin of 30.2%  and adjusted earnings per share (EPS) of 38.8p in Q2 2023.

GSK has generated £1.6bn cash from its operations in the second quarter of 2023, an increase of 3% from the same quarter of 2022.

Its vaccine sales saw a boost of 18%, while general medicine sales grew by 8%.

Products launched since 2017, particularly in the areas of vaccines and HIV, have led to a significant increase in sales growth and overall performance.

Upgrading its 2023 guidance, GSK anticipates that turnover will be in the range of 8% to 10%, up from the previous 6% to 8%, with its adjusted operating profit growth in the range of 11% to 13% and EPS rising from 14% to 17%.

GSK CEO Emma Walmsley stated: “We have delivered another excellent quarter of performance, with strong sales and earnings growth, notably in HIV and vaccines, and continued strengthening of the research and development pipeline and product portfolio.

“The approval of Arexvy, the world’s first RSV [respiratory syncytial virus] vaccine, was an important milestone for us and is at the forefront of the next wave in vaccine innovation for GSK.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close